PLAG1重排儿童纤维黏液样肿瘤:支持为脂肪母细胞瘤形态谱系的10例分析
该研究纳入10例儿童PLAG1重排纤维黏液样肿瘤(P-FMT),进行临床病理、分子及表观遗传学分析。P-FMT与纤维型脂肪母细胞瘤形态相似,具有相同免疫表型、PLAG1重排及重叠融合伴侣、共同DNA甲基化特征和良性行为,支持将其归类为脂肪母细胞瘤的纤维型或低脂肪分化亚型,而非独立实体。
要点
- P-FMT呈纤维黏液样形态,CD34和desmin阳性,可与脂肪母细胞瘤谱系归为一类。
- P-FMT与脂肪母细胞瘤共享PLAG1重排、重叠融合伴侣及DNA甲基化特征。
- 随访患者均呈良性行为,无复发,支持其惰性生物学特性。
核心结论
- P-FMT应归类为脂肪母细胞瘤谱系内的纤维型或低脂肪分化亚型,而非独立实体。
研究设计与样本
- 回顾性队列研究,纳入10例P-FMT(5男5女,年龄3个月至10岁,中位4岁),进行临床病理、分子及表观遗传学综合分析。
主要发现
- 所有肿瘤均边界清楚,由温和的纤维母细胞性梭形细胞构成,位于胶原性至黏液样间质中,2例局灶含成熟脂肪细胞。
- 所有肿瘤表达CD34和desmin,并经FISH或分子测序确认PLAG1重排,融合伴侣包括COL1A2(n=3)、MEG3(n=2)、BOC(n=1)、YWHAZ(n=1)、EEF1A1(n=1)、CHCHD7(n=1)。
- DNA甲基化谱分析显示所有P-FMT与脂肪母细胞瘤聚类在一起,并与其他间叶性肿瘤分离。
- 拷贝数谱显示P-FMT和脂肪母细胞瘤均存在统计学显著的8号染色体获得。
- 有随访病例(中位22个月)均呈良性行为,无复发。
临床怎么用
- 病理诊断中遇儿童纤维黏液样肿瘤伴CD34和desmin阳性时,应检测PLAG1重排以考虑P-FMT。
- 确诊P-FMT后可按脂肪母细胞瘤谱系进行管理,避免过度治疗。
局限性
- 样本量小(n=10),随访时间有限(中位22个月),需更大队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
P-FMT histologically resembles fibroblastic lipoblastoma and has similar gene fusions, DNA methylation profiles, and benign clinical behaviour, supporting classification of P-FMT as a morphological variant of lipoblastoma. Aim Paediatric PLAG1-rearranged fibromyxoid tumour (P-FMT) is an emerging soft-tissue neoplasm characterized by predominantly fibromyxoid morphology, minimal to absent adipocytic differentiation and consistent CD34 and desmin positivity. It is debated whether P-FMT represents a distinct entity or a morphological variant of lipoblastoma. We aim to better characterize P-FMT and assess its relationship with lipoblastoma. Methods and results We assembled the largest cohort of P-FMT (n = 10) and performed comprehensive clinicopathological, molecular and epigenetic characterization. The cohort comprised five males and five females, aged 3 months to 10 years (median 4 years), with tumours arising in the extremities, trunk and neck. Histologically, all were well-demarcated lesions with bland fibroblastic spindle cells in collagenous to myxoid stroma; two cases focally contained mature adipocytes. All tumours expressed CD34 and desmin. PLAG1 rearrangements were confirmed by fluorescence in situ hybridization or molecular sequencing, with fusion partners identified as COL1A2 (n = 3), MEG3 (n = 2), BOC (n = 1), YWHAZ (n = 1), EEF1A1 (n = 1) and CHCHD7 (n = 1). DNA methylation profiling demonstrated that all P-FMTs grouped with lipoblastoma on hierarchical clustering and dimensionality reduction analysis and segregated from other mesenchymal tumours. Copy number profiles showed statistically significant chromosome 8 gain in both P-FMT and lipoblastoma. All cases with follow-up (median 22 months) demonstrated benign behaviour without recurrence. Conclusions Our findings of morphological resemblance to fibroblastic lipoblastoma and multiple similarities to classic lipoblastoma, including identical immunophenotype, PLAG1 rearrangements with overlapping partners, common epigenetic signature and uniformly benign behaviour, support classification of P-FMT as a fibroblastic or minimally adipocytic subtype within the lipoblastoma spectrum, rather than a distinct entity.
引用
- Histopathology:PLAG1‐rearranged paediatric fibromyxoid tumour: clinicopathological, molecular and epigenetic analysis of 10 cases supporting a morphological spectrum with lipoblastoma
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。